Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Quinn

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Communicable Diseases Intelligence (2018)|January 11, 2019
Surveillance of adverse events following immunisation in Australia annual report, 2016Aditi Dey, Han Wang, Helen Quinn, et al.
Communicable Diseases Intelligence Quarterly Report|May 4, 2018
Surveillance of adverse events following immunisation in Australia, 2015Aditi Dey, Han Wang, Helen Quinn, et al.
Vaccine|June 27, 2025
Reduction in self-reported adverse events in Australian adults after change to national immunisation schedule from polysaccharide to conjugate pneumococcal vaccine, 2016-2022Zoë Croker, Angus McLure, Alexis Pillsbury, et al.
Vaccine|September 16, 2008
Evaluation of recombinant proteins of Neospora caninum as vaccine candidates (in a mouse model)John Ellis, Catherine Miller, Helen Quinn, et al.
The Journal of Antimicrobial Chemotherapy|June 21, 2019
Social norm feedback reduces primary care antibiotic prescribing in a regression discontinuity studyDeclan T Bradley, Sarah E Allen, Helen Quinn, et al.
The Pediatric Infectious Disease Journal|September 3, 2010
Severe pertussis in infants: estimated impact of first vaccine dose at 6 versus 8 weeks in australiaAlice Ruth Foxwell, Peter McIntyre, Helen Quinn, et al.
Musculoskeletal Care|July 28, 2007
Patient priorities of care in rheumatology outpatient clinics: a qualitative studyVicky Ward, Jackie Hill, Claire Hale, et al.
Vaccine|April 23, 2023
Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccinesAlexis Pillsbury, Anastasia Phillips, Lucy Deng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 23, 2018
Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational StudySanjay Jayasinghe, Clayton Chiu, Helen Quinn, et al.
International Journal for Parasitology|May 12, 2005
Reduction in transplacental transmission of Neospora caninum in outbred mice by vaccinationCatherine Miller, Helen Quinn, Cheryl Ryce, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Communicable Diseases Intelligence (2018)|January 11, 2019
Surveillance of adverse events following immunisation in Australia annual report, 2016Aditi Dey, Han Wang, Helen Quinn, et al.
Communicable Diseases Intelligence Quarterly Report|May 4, 2018
Surveillance of adverse events following immunisation in Australia, 2015Aditi Dey, Han Wang, Helen Quinn, et al.
Vaccine|June 27, 2025
Reduction in self-reported adverse events in Australian adults after change to national immunisation schedule from polysaccharide to conjugate pneumococcal vaccine, 2016-2022Zoë Croker, Angus McLure, Alexis Pillsbury, et al.
Vaccine|September 16, 2008
Evaluation of recombinant proteins of Neospora caninum as vaccine candidates (in a mouse model)John Ellis, Catherine Miller, Helen Quinn, et al.
The Journal of Antimicrobial Chemotherapy|June 21, 2019
Social norm feedback reduces primary care antibiotic prescribing in a regression discontinuity studyDeclan T Bradley, Sarah E Allen, Helen Quinn, et al.
The Pediatric Infectious Disease Journal|September 3, 2010
Severe pertussis in infants: estimated impact of first vaccine dose at 6 versus 8 weeks in australiaAlice Ruth Foxwell, Peter McIntyre, Helen Quinn, et al.
Musculoskeletal Care|July 28, 2007
Patient priorities of care in rheumatology outpatient clinics: a qualitative studyVicky Ward, Jackie Hill, Claire Hale, et al.
Vaccine|April 23, 2023
Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccinesAlexis Pillsbury, Anastasia Phillips, Lucy Deng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 23, 2018
Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational StudySanjay Jayasinghe, Clayton Chiu, Helen Quinn, et al.
International Journal for Parasitology|May 12, 2005
Reduction in transplacental transmission of Neospora caninum in outbred mice by vaccinationCatherine Miller, Helen Quinn, Cheryl Ryce, et al.
Pageof 5